International Journal of Cancer最新文献

{"title":"Breast cancer survival by stage at diagnosis in countries in transition: A population-based study.","authors":"Hanna Fink, Eileen Morgan, Aude Bardot, Daniel Jurado, Wilmer Tarupi, Supakorn Pitakkarnkul, Aleyamma Mathew, Rama Ranganathan, Luisa Bravo Goyes, Freddy Gnangnon, Guledal Boztas, Isabelle Soerjomataram","doi":"10.1002/ijc.70353","DOIUrl":"10.1002/ijc.70353","url":null,"abstract":"<p><p>This study explores variation in stage-specific survival in women diagnosed with breast cancer in transitioning countries. We obtained data of women diagnosed between 2008 and 2012 from 11 population-based cancer registries (PBCRs) in 10 countries, with follow-up until December 2014. Following stage data standardization and multiple imputation for missing data, we estimated age-standardized 1-, 3-, and 5-year net survival (ASNS) by stage and age group. Stage distribution varied significantly across jurisdictions. Puerto Rico had over 4 in 5 patients diagnosed with early stage (stage I/II), while India, Trivandrum, and Thailand, Khon Kaen had <3 in 5 diagnosed with early stage. Stage-specific ASNS was similar across early stages (stage I/II) but varied markedly for stage IV, where the highest 3-year ASNS (Puerto Rico: 43.2% 95% CI: 38.9%-47.6%) was 20 percentage points higher than the lowest 3-year ASNS (India, Trivandrum: 22.8% 95% CI: 10.2%-35.4%). ASNS for patients 60 years and older was generally lower than for patients younger than 60 years across all jurisdictions. Differences in ASNS were subtle in early stages but were especially pronounced for stage IV, where in Puerto Rico, 3-year ASNS for patients younger than 60 (49.0% 95% CI: 42.7%-55.2%) was over 13 percentage points higher than 3-year ASNS for patients 60 or older (35.4% 95% CI: 29.2%-41.7%). Disparities in breast cancer survival were partly explained by differences in early diagnosis and in care at late stages. Stage at diagnosis is an important indicator that should be collected by registries worldwide, particularly for late-stage disease and older patients.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":"92-100"},"PeriodicalIF":4.7,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146049862","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immune, molecular and genetic profiles of gastric signet ring cell carcinoma: Recent progress and future challenges.","authors":"Qian Wang, Shuai Zhou, Xiongchao Fang, Xianli He, Gang Wang, Nan Wang","doi":"10.1002/ijc.70416","DOIUrl":"10.1002/ijc.70416","url":null,"abstract":"<p><p>Gastric signet ring cell carcinoma (GSRCC) is a special type of gastric cancer common in young women. Diffuse gastric cancer (DGC) begins with intramucosal lesions comprising differentiated GSRCC cells. Genetically, GSRCC and DGC are clonally identical, with their morphology influenced by extracellular Wnt signaling. Interestingly, Wnt activation facilitates the transition of indolent GSRCC cells into more invasive DGC cells, indicating the high plasticity of GSRCC cells. With respect to its cellular origin, GSRCC may originate from MUC5AC-/MUC6- pre-pit cells in the proliferative area of the gastric gland. Importantly, the tumor immune microenvironment (TIM) of GSRCC has unique characteristics. Compared with that of non-GSRCC, the TIM of GSRCC seems to be in a relatively \"quiescent\" state, and CD4⁺ and CD8⁺ T cells are difficult to activate. Moreover, compared with non-GSRCC patients, GSRCC patients have significantly greater Treg infiltration and significantly fewer CD8⁺ T effector cells. This immune \"quiescent\" state may explain the poor response to immunotherapy in patients with GSRCC. Notably, the depletion of CXCL13 derived from exhausted CD8⁺ T cells (CD8-Tex) and the absence of mature tertiary lymphoid structures are key reasons for the low response to immunotherapy in patients with GSRCC. Therefore, for patients with GSRCC, enhancing the ability of CD8-Tex cells to produce CXCL13 may be the key to improving the immune therapy response. In this review, we explore recent key findings on GSRCC, focusing on molecular mechanisms, immune regulation, and prospective research directions to improve clinical applications.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":"11-29"},"PeriodicalIF":4.7,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13139998/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147525138","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trabectedin in the treatment of soft tissue sarcoma: Real-world data on effectiveness, safety, and financial implications from a European comprehensive cancer center.","authors":"Jean-Stéphane Giraud, Sarah Watson, Alexandre Acramel, Valérie Laurence, Dimitri Tzanis, Sylvie Bonvalot, Sophie El Zein, Nayla Nicolas, Cyrille Cros, Romain Desmaris, Clément Bonnet","doi":"10.1002/ijc.70403","DOIUrl":"10.1002/ijc.70403","url":null,"abstract":"<p><p>Soft-tissue sarcomas (STS) comprise over 150 histological subtypes, with advanced cases showing poor prognosis (5-year survival <10%). Trabectedin, a synthetic alkaloid, is frequently used after anthracycline-based chemotherapy failure. Despite the withdrawal of reimbursement in France in 2016 due to debated efficacy and safety, it remains in clinical use, imposing financial strain on hospitals. This retrospective single-center study evaluated trabectedin's efficacy, safety, and cost in 68 patients treated between 2019 and 2023. L-sarcomas accounted for 78% of cases, including uterine leiomyosarcomas (n = 16), soft-tissue leiomyosarcomas (n = 17), and myxoid liposarcomas (n = 8). Non-L-sarcomas (22%) included mostly synovial sarcomas. The overall disease control rate was 71%, with a median progression-free survival (PFS) of 4.1 months, and an overall survival of 12.3 months. Subtype-specific median PFS was 6.8 months for liposarcomas (11.3 for myxoid vs. 4.5 for other subtypes), 3.1 months for leiomyosarcomas (3.4 months for uterine vs. 3.1 for soft-tissue), and 2.4 months for non-L-sarcomas. Patients received a median of 5 cycles (range: 1-38), with an average total dose of 16 mg [2-81], and an average hospital cost of €9900. Adverse events occurred in 91%, mainly hematological; cardiac toxicity was seen in 9%. This retrospective single-center study in a limited cohort provides real-world insights but should be interpreted with caution. Despite limited reimbursement, trabectedin may retain clinical utility, particularly in L-sarcoma management.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":"234-243"},"PeriodicalIF":4.7,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147281607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of ≥2 lines immunotherapy regimens for recurrent/metastatic nasopharyngeal carcinoma.","authors":"Lan Peng, Xi Ding, Rui-Chao Zou, Rui You, You-Ping Liu, Jiong-Lin Liang, Si-Yuan Chen, Yan-Feng Ouyang, Ge-Er Long, Ming-Yuan Chen","doi":"10.1002/ijc.70399","DOIUrl":"10.1002/ijc.70399","url":null,"abstract":"<p><p>Patients with recurrent/metastatic nasopharyngeal carcinoma (RM-NPC) do not yet have a strong recommended regimen after failure of first-line systemic therapy. This study retrospectively analyzed the efficacy of immunotherapy regimens in RM-NPC that failed at least first-line therapy. From February 2014 to August 2023, a total of 794 patients with RM-NPC were included in this study, of which 75 patients received anti-programmed cell death protein-1 (PD-1) only (P), 130 patients received anti-PD-1 plus antiangiogenic therapy (AP), 210 patients received anti-PD-1 plus single-agent chemotherapy (C1P), 276 patients received anti-PD-1 plus two-agent chemotherapy (C2P), and 103 patients received anti-PD-1 plus antiangiogenic plus chemotherapy (CAP). Progression-free survival (PFS), overall survival (OS), and adverse events were analyzed. In the inverse probability of treatment weighting (IPTW) cohort, median follow-up time was 28.7 months, median PFS in the P, AP, C1P, C2P, and CAP were 3.6, 8.5, 7.6, 12.7, and 16.3 months, respectively. PFS was significantly better in the CAP, C2P, C1P, and AP than P (p values of <.001, <.001, .026, and .002). Median OS in the P, AP, C1P, C2P, and CAP were 35.8, 46.6, 50.9, 50.6, and 47.2 months, respectively. Grade 3-4 treatment-related adverse events (TRAEs) occurred in 288 patients, with rates significantly higher in the C1P than AP (34.3% vs. 16.9%) and higher in the C2P than CAP (54.0% vs. 42.7%). These results showed that, in RM-NPC patients who failed at least first-line therapy, anti-PD-1 combination therapy was associated with improved PFS compared with anti-PD-1 monotherapy.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":"224-233"},"PeriodicalIF":4.7,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147269155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world progression-free survival and overall survival in patients with HR⁺/HER2^- advanced breast cancer treated in first-line with ribociclib, endocrine monotherapy or chemotherapy: Results from the observational RIBANNA study.","authors":"Peter A Fasching, Cosima Brucker, Thomas Decker, Anne Engel, Thomas Göhler, Christian Jackisch, Jan Janssen, Andreas Köhler, Kerstin Lüdtke-Heckenkamp, Diana Lüftner, Frederik Marmé, Marion van Mackelenbergh, Beate Rautenberg, Marcus Schmidt, Rudolf Weide, Pauline Wimberger, Elena Kisseleff, Christina Pfister, Claudia Quiering, Christian Roos, Achim Wöckel","doi":"10.1002/ijc.70397","DOIUrl":"10.1002/ijc.70397","url":null,"abstract":"<p><p>Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) combined with endocrine therapy are the preferred choice for first-line treatment of patients with HR⁺/HER2^- locally advanced/metastatic breast cancer (aBC). The CDK4/6i ribociclib in combination with an aromatase inhibitor (AI) or fulvestrant (FUL) has demonstrated significant progression-free survival (PFS) and overall survival (OS) benefits for pre- and postmenopausal aBC patients who were enrolled in the three pivotal MONALEESA trials. Following the initial approval of ribociclib in 2017, the non-interventional RIBANNA study was initiated to evaluate the effectiveness and safety of ribociclib plus AI/FUL therapy among patients with aBC in a real-world setting. Two additional treatment cohorts (endocrine monotherapy [ET] and chemotherapy [CT]) were included to extend the knowledge about current aBC treatments. A total of 2567 patients were enrolled in 279 study centers, of whom 1852 were treated with ribociclib+AI/FUL, 183 were treated with ET, and 139 were treated with CT, who were available for effectiveness analyses. Median PFS (mPFS) and median OS (mOS) on first-line treatment with ribociclib+AI/FUL were 35.0 and 76.0 months, respectively. Adjustment for differences in demographic and baseline characteristics resulted in a longer mPFS on ribociclib+AI/FUL (34.7 months) compared to ET (26.4 months) or CT (19.2 months). Adverse events (AEs) on ribociclib were consistent with those seen in the pivotal trials, and no new safety signals were observed. The RIBANNA study confirmed the PFS and OS benefit seen in the MONALEESA trials. Together with the safety data, this large real-world dataset supports the favorable risk/benefit profile of ribociclib in large scale patient populations.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":"210-223"},"PeriodicalIF":4.7,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13139987/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147369115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global patterns and trends in kidney cancer incidence and mortality.","authors":"Anton Barchuk, Jerome Vignat, Kari A O Tikkinen, Ahmedin Jemal, Freddie Bray, Ariana Znaor","doi":"10.1002/ijc.70349","DOIUrl":"10.1002/ijc.70349","url":null,"abstract":"<p><p>This study provides an update on global patterns and trends in kidney cancer incidence and mortality. We used the most recent GLOBOCAN estimates, based on the best available data sources, including population-based cancer registries (PBCRs), to compare incidence and mortality in 185 countries or territories in 2022 and to assess time trends based on recorded PBCR and vital statistics data in 71 countries. Incidence age-standardised rates (ASRs) varied 10-fold across UN regions and 20-fold at the country level in 2022. Kidney cancer ASRs were consistently higher in males than females and ranged from 1.6 per 100,000 in low Human Development Index (HDI) countries to 12.6 in very high HDI countries among men and from 1.1 to 5.9 among women. The highest ASRs in males were in Belarus (22.9), Uruguay (20.5), and Latvia (19.2), and in females in Latvia (9.5), Uruguay (8.7), USA (8.7). While the patterns were similar for mortality, variations were less pronounced. The mortality-to-incidence ratio was lowest in Oceania (0.2) and highest in Africa (0.7). Over the past 15 years, incidence ASRs have tended to increase or stabilise in most European countries, Northern America and Oceania, but increased in Asia and Latin America. Mortality ASRs decreased in most countries, but increased in Portugal, Romania, Moldova, the Philippines, Malaysia and in 9 of 14 countries in Latin America. Regional variations in incidence call for a greater focus on risk factors amenable to prevention, coupled with an assessment of the role of diagnostics. The varied mortality patterns indicate present treatment inequalities.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":"67-77"},"PeriodicalIF":4.7,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13140048/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146083549","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is the beneficial effect of multi-cohort HPV vaccination on cervical cancer and precancerous lesions seen across all educational levels?","authors":"Rose M W Rasmussen, Christian Munk, Susanne K Kjær","doi":"10.1002/ijc.70360","DOIUrl":"10.1002/ijc.70360","url":null,"abstract":"<p><p>Human papillomavirus (HPV) vaccination, implemented in multi-cohort vaccination programs in Denmark since 2008, has led to a decrease in the incidence of cervical cancer and cervical intraepithelial neoplasia grade 3 (CIN3). However, it remains unclear if the beneficial impact of this vaccination approach applies to all educational levels. In the present study, we estimated the incidence of cervical cancer and CIN3 during 2006-2023, overall and stratified by education. Information on all cases of cervical cancer and CIN3 and on education was obtained from high-quality, nationwide registries. We calculated age-standardized and age-specific incidence rates and calculated estimated annual percentage change (EAPC) with corresponding 95% confidence intervals (CI) for the early HPV vaccination period (2006-2012) and the late HPV vaccination period (2013-2023). We observed a decrease in age-standardized incidence of cervical cancer in the late vaccination period only among women with medium or long education. Impact was particularly found among women aged 20-29 years with medium (EAPC_{2013-2023[medium]} = -14.2, 95% CI: -15.9; -12.5) or long (EAPC_{2013-2023[long]} = -13.9, 95% CI: -15.1; -12.7) education. For CIN3, an increase in incidence was seen in the early vaccination period followed by a significant decrease in the late vaccination period, overall and stratified by education. However, in age-specific analyses, the decrease was only seen for the youngest women. Even in a country with free-of-charge multicohort HPV vaccination programs, the beneficial impact was most apparent among women with medium or long education, suggesting that educational inequalities still exist.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":"111-121"},"PeriodicalIF":4.7,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146123163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oxaliplatin-induced neuropathy after total neoadjuvant therapy for rectal cancer: Dose-response relationship and impact on quality of life.","authors":"Georg W Wurschi, Andreas Hinz, Melanie Schneider, Jan-Niklas Becker, Bernd Frerker, Samuel M Vorbach, Felix Ehret, Markus Diefenhardt, Fabian Schunn, Maria-Elena von Gruben, Marcel Büttner, Elgin Hoffmann, Alexander Rühle, Josephine Beier, Simone Ferdinandus, Maike Trommer, Ezgi Ceren Sahin, Julian Hlouschek, Kynann Aninditha, Daphne Schepers von Ohlen, Justus Kaufmann, Alina Depardon, Hai Minh Ha, Christopher Kessler, Adrianna Cieslak, Simon Trommer, Alexander Fabian, Florian Rißner, Maximilian Römer, Klaus Pietschmann","doi":"10.1002/ijc.70396","DOIUrl":"10.1002/ijc.70396","url":null,"abstract":"<p><p>Oxaliplatin-based regimens are increasingly used in total neoadjuvant therapy (TNT) for locally advanced rectal cancer, frequently causing dose-limiting chemotherapy-induced peripheral neuropathy (CIPN), whose extent and impact on health-related quality of life (HrQoL) remain insufficiently characterized. The optimal duration and intensity of chemotherapy within TNT for tumor response and toxicity remain unclear. This retrospective multicenter study (DRKS00033000) assessed the dose-response relationship of CIPN with cumulative oxaliplatin dose (cOXAd) and its impact on HrQoL. A total of 227 patients (164 men) with a median age of 63 (Q1-Q3: 54-68) years, who underwent oxaliplatin-based TNT between 2015 and 2024, were analyzed. HrQoL was assessed cross-sectionally during follow-up using the EORTC QLQ-C30 and QLQ-CIPN20 questionnaires. Multivariable logistic regression was applied to evaluate the relationship between cOXAd and CIPN grade ≥2, and known-group comparisons examined differences in HrQoL scores. At follow-up, 61 patients (26.9%) experienced CIPN grade ≥2 after a median cOXAd of 758.8 mg/m². Higher cOXAd was associated with an increased likelihood of CIPN grade ≥2 (adjusted OR 1.004, 95% CI: 1.002-1.007), corresponding to a 7.8% higher probability per additional FOLFOX cycle (+85 mg/m² cOXAd). Patients with CIPN grade ≥2 reported lower mean QLQ-C30 Global Health Scores and Summary Scores (-13.0 and -12.4 points; Cohen's d = -0.59 and -0.68) and higher QLQ-CIPN20 Summary Scores (+23.9 points; Cohen's d = 1.65) compared to those without CIPN. These findings indicate that CIPN is a common dose-dependent toxicity of oxaliplatin-based TNT, associated with considerably reduced HrQoL and markedly increased neuropathy-related symptom burden at follow-up.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":"198-209"},"PeriodicalIF":4.7,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13140008/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146211586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The mediating role of the kynurenine pathway in longitudinal associations between dietary intake and quality of life in colorectal cancer survivors up to 12 months posttreatment.","authors":"Daniëlle D B Holthuijsen, Judith J M Rijnhart, Eline H van Roekel, Martijn J L Bours, Per M Ueland, Stéphanie O Breukink, Maryska L G Janssen-Heijnen, Joop L Konsten, Eric T P Keulen, Adrian McCann, Stefanie Brezina, Biljana Gigic, Jennifer Ose, Matty P Weijenberg, Simone J P M Eussen","doi":"10.1002/ijc.70363","DOIUrl":"10.1002/ijc.70363","url":null,"abstract":"<p><p>Previous research has revealed associations between diet and health-related quality of life (HRQoL), between diet and kynurenine pathway (KP) metabolites (kynurenines), and between kynurenines and HRQoL in colorectal cancer (CRC) survivors. We examined if kynurenines mediate longitudinal associations between diet and HRQoL in CRC survivors up to 12-months posttreatment. Repeated measurements were performed in 209 stage I-III CRC survivors. Diet was assessed by seven-day dietary records. Plasma kynurenines were analyzed using LC-MS/MS. HRQoL outcomes were assessed through the validated EORTC QLQ-C30. We used confounder-adjusted multilevel parallel-multiple mediator models with all kynurenines simultaneously and single mediator models with established KP ratios to estimate total (c:diet-HRQoL), direct (c':diet-HRQoL), metabolite-specific indirect (ab: diet-metabolite-HRQoL), and total indirect (ab:diet-metabolites-HRQoL) effects. Higher carbohydrate intake was associated with worse role functioning, while higher fiber, alcohol, and zinc intake, and better adherence to the Dutch Healthy Diet (DHD) recommendations were associated with better physical and role functioning (c-path). Associations of fiber and DHD with HRQoL remained statistically significant after controlling for all KP metabolites (c'-path). All kynurenines simultaneously only mediated associations of higher carbohydrate intake with worse role functioning, and of higher alcohol intake with better physical functioning (ab). The kynurenic acid-to-quinolinic acid (KA/QA) ratio and hydroxykynurenine ratio (HKr) significantly mediated associations of carbohydrate, protein, fat, alcohol, magnesium, and zinc intake, and adherence to DHD recommendations, with physical and role functioning (ab). In conclusion, while all kynurenines simultaneously did not mediate diet-HRQoL associations, the KA/QA ratio and HKr did mediate several associations within the first year after CRC treatment.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":"122-143"},"PeriodicalIF":4.7,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13140012/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147281573","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SGLT2 inhibitors mitigate cardiorenal toxicity and improve survival in type 2 diabetes mellitus patients undergoing antineoplastic therapy: A multicenter retrospective cohort study.","authors":"Yueyan Zhao, Yanli Zhang, Mingyue Ju, Ying Liu","doi":"10.1002/ijc.70389","DOIUrl":"10.1002/ijc.70389","url":null,"abstract":"<p><p>Asia faces a rising cancer burden, with type 2 diabetes mellitus (T2DM) prevalence in cancer patients at 24.4% (2.3-fold higher than that of the general population). Antineoplastic therapies (e.g., anthracyclines and vascular endothelial growth factor receptor [VEGFR] inhibitors) increase cardiorenal toxicity, exacerbated by T2DM. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) benefit non-oncologic populations but are understudied in T2DM-cancer patients. We assessed SGLT2i's effects on antineoplastic-related cardiorenal toxicity/survival via a multicenter retrospective cohort of 248 T2DM-cancer patients (56.0% male, mean age 66.7 years) 1:1 divided into SGLT2i/non-SGLT2i groups. Over 30.4 months of follow-up, SGLT2i reduced cardiovascular events by 86.1% (odds ratio [OR] = 0.139, 95% CI 0.027-0.710, p = .018) and all-cause mortality by 84.7% (HR = 0.153, 95% CI 0.055-0.431, p < .001). Echocardiography showed improved left ventricular ejection fraction (LVEF) and reduced left ventricular end-diastolic diameter (LVID)/left atrial (LA) dimensions (all p < .001). Despite lower baseline estimated glomerular filtration rate (eGFR) in the SGLT2i group, SGLT2i preserved renal function (post-treatment eGFR: 99.8 vs. 67.5 mL/min/1.73 m²; p = .054) and reduced uric acid (UA) levels by 23.6% (p < .001). Benefits persisted across solid tumor/hematological malignancies and anthracycline-based therapy, targeted antineoplastic therapy or immunotherapy subgroups, with no increase in infection. SGLT2i improve cardiorenal outcomes and survival in T2DM-cancer patients warranting prospective validation.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":"173-187"},"PeriodicalIF":4.7,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147484060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}